Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Structure of Cannabinoid Receptor Elucidated In New Study

XTALKS VITALS NEWS

Cannabis

According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

Share this!

October 24, 2016 | by Sarah Hand, M.Sc.

While researchers have long known that one of the active component in cannabis – known as tetrahydrocannabinol (THC) – acts on the cannabinoid receptors in the brain, the mechanisms behind this interaction were previously unknown. Now, researchers have uncovered the structure of the cannabinoid receptor 1 (CB1), in a study which was published in the journal Cell.

Using this crystal structure, the researchers were able to create a 3-D model of the CB1 receptor. According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

“With marijuana becoming more popular with legislation in the United States, we need to understand how molecules like THC and the synthetic cannabinoids interact with the receptor,” said co-author Raymond Stevens, a professor of Biological Science and Chemistry at the University of Southern California, “especially since we're starting to see people show up in emergency rooms when they use synthetic cannabinoids.”



According to the researchers, it’s unknown why THC derived from Cannabis sativa has such a high safety margin, compared to synthetic cannabinoids which can cause serious side effects in certain doses. Their research on the structure of CB1 could help drugmakers design safer therapeutics capable of acting on the receptor.

By synthesizing a synthetic cannabinoid known as AM6538, Stevens and his team were able to determine the conformation of the CB1 receptor. When studying the 3-D model of the CB1 receptor, the researchers identified multiple regions which may explain how THC and synthetic cannabinoids produce psychoactive effects on the body.

“Researchers are fascinated by how you can make changes in THC or synthetic cannabinoids and have such different effects,” said Stevens. “Now that we finally have the structure of CB1, we can start to understand how these changes to the drug structure can affect the receptor.”


Keywords: Cannabis, Drug Development, Drug Receptor


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.